




Searching News Database: alemtuzumab
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 16 Feb 2011
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
HSMN NewsFeed - 3 Nov 2009
Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer
Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer
HSMN NewsFeed - 30 Apr 2007
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
HSMN NewsFeed - 21 Jun 2006
Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor Program to Schering AG
Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor Program to Schering AG
Additional items found! 20

Members Archive contains
20 additional stories matching:
alemtuzumab
(Password required)
alemtuzumab
(Password required)